AAPS PharmSciTech

, Volume 6, Issue 3, pp E536–E542 | Cite as

Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled sitespecific delivery of acidic anti-inflammatory active ingredient

  • Abhay Asthana
  • Abhay Singh Chauhan
  • Prakash Vamanrao Diwan
  • Narendra Kumar Jain


The purpose of the investigation was to evaluate the potential of polyamidoamine (PAMAM) dendrimer as nanoscale drug delivery units for controlled release of water insoluble and acidic anti-inflammatory drug. Flurbiprofen (FB) was selected as a model acidic anti-inflammatory drug. The aqueous solutions of 4.0 generation (G) PAMAM dendrimer in different concentrations were prepared and used further for solubilizing FB. Formation of dendrimer complex was characterized by Fourier transform infrared spectroscopy. The effect of pH on the solubility of FB in dendrimer was evaluated. Dendrimer formulations were further evaluated for in vitro release study and hemolytic toxicity. Pharmacokinetic and biodistribution were studied in male albino rats. Efficacy of dendrimer formulation was tested by carrageenan induced paw edema model. It was observed that the loaded drug displayed initial rapid release (more than 40% till 3rd hour) followed by rather slow release. Pharmacodynamic study revealed 75% inhibition at 4th hour that was maintained above 50% till 8th hour. The mean residence time (MRT) and terminal half-life (THF) of the dendritic formulation increased by 2-fold and 3-fold, respectively, compared with free drug. Hence, with dendritic system the drug is retained for longer duration in the biosystem with 5-fold greater distribution. It may be concluded that the drug-loaded dendrimers not only enhanced the solubility but also controlled the delivery of the bioactive with localized action at the site of inflammation.


dendrimer flurbiprofen in vitro studies pharmacokinetics biodistribution 


  1. 1.
    Beezer AE, King ASH, Martin IK, Mitchel JC, Twyman LJ, Wain CF. Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives.Tetrahedron. 2003;59:3873–3880.CrossRefGoogle Scholar
  2. 2.
    Patri AK Jr, Majoros IJ Jr, Baker JR Jr. Dendritic polymer macromolecular carriers for drug delivery.Curr Opin Chem Biol. 2002;6:466–471.CrossRefGoogle Scholar
  3. 3.
    Bosman AW, Janssen HM, Meijer EW. About dendrimers: structure, physical properties, and applications.Chem Rev. 1999;99:1665–1688.CrossRefGoogle Scholar
  4. 4.
    Milhem OM, Myles C, McKeown NB, Attwood D, Emanuele AD. Polyamidoamine starburst dendrimers as solubility enhancers.Int J Pharm. 2000;197:239–241.CrossRefGoogle Scholar
  5. 5.
    Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers.Int J Pharm. 2003;259:143–160.CrossRefGoogle Scholar
  6. 6.
    Zeng F, Zimmerman SC. Dendrimers in supramolecular chemistry: from molecular recognition to self-assembly.Chem Rev. 1997; 97:1681–1712.CrossRefGoogle Scholar
  7. 7.
    Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin.J Control Release. 2003;90:335–343.CrossRefGoogle Scholar
  8. 8.
    Khopade AJ, Caruso F, Tripathi P, Nagaich S, Jain NK. Effect of dendrimer on entrapment and release of bioactive from liposomes.Int J Pharm. 2002;232:157–162.CrossRefGoogle Scholar
  9. 9.
    Khopade AJ, Shenoy DB, Khopade SA, Jain NK. Phase structures of a hydrogenated anionic phospholipid composition containing cationic dendrimers and pegylated lipids.Langmuir. 2004;20:7368–7373.CrossRefGoogle Scholar
  10. 10.
    Park KM, Kim CK. Preparation and evaluation of flurbiprofenloaded microemulsion for parenteral delivery.Int J Pharm. 1999;181:173–179.CrossRefGoogle Scholar
  11. 11.
    Park KM, Lee MK, Hwang KJ, Kim CK. Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process.Int J Pharm. 1999;183:145–154.CrossRefGoogle Scholar
  12. 12.
    Government of India.Indian Pharmacopoeia. New Delhi, India: Ministry of Health and Family Welfare, Controller of Publications; 1996:328.Google Scholar
  13. 13.
    Singhai AK, Jain S, Jain NK. Evaluation of an aqueous injection of ketoprofen.Pharmazie. 1997;52:149–151.Google Scholar
  14. 14.
    Chauhan AS, Jain NK, Diwan PV, Khopade AJ. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats.J Drug Target. 2004;12:575–583.CrossRefGoogle Scholar
  15. 15.
    Bhadra D, Bhadra S, Jain S, Jain NKA. PEGylated dendritic nanoparticulate carrier of fluorouracil.Int J Pharm. 2003;257:111–124.CrossRefGoogle Scholar
  16. 16.
    Hardman JG, Limbird LE, Molinoff PB, Ruddeon RW, Gilman AG.Goodman and Gilman's the Pharmacological Basis of Therapeutics, Vol 9. New York, NY: McGraw-Hill; 1996:640–647.Google Scholar
  17. 17.
    Kissel M, Peschke P, Subr V, et al. Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors.PDA J Pharm Sci Technol. 2001;55:191–201.Google Scholar
  18. 18.
    Crommelin DJA, Hennik WE, Strom G. Drug targeting systems: fundamentals and applications to parenteral drug delivery. In: Hillery AM, Lloyd AW, Swarbrick J, eds.Drug Delivery and Targeting. New York, NY: Taylor and Francis Inc; 2001:119–125.Google Scholar
  19. 19.
    Klajnert B, Stanislawska L, Bryszewska M, Palecz B. Interactions between PAMAM dendrimers and bovine serum albumin.Biochim Biophys Acta. 2003;1648:115–126.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2005

Authors and Affiliations

  • Abhay Asthana
    • 1
  • Abhay Singh Chauhan
    • 2
  • Prakash Vamanrao Diwan
    • 2
  • Narendra Kumar Jain
    • 1
  1. 1.Department of Pharmaceutical SciencesDr. H. S. Gour UniversitySagarIndia
  2. 2.Pharmacology DivisionIndian Institute of Chemical TechnologyTarnakaIndia

Personalised recommendations